NCT06179537

Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects

A Phase I, Double-Blind, Randomised, Adaptive-designed Study to Assess the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects Following Single and Multiple Oral Doses

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Bellus Health Inc. - a GSK company · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This is a Phase I, Double-Blind, Randomised, Adaptive-designed Study to Assess the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects Following Single and Multiple Oral Doses

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	BLU-5937	Single and multiple doses assessment

Timeline

• Start date: 2021-08-06
• Primary completion: 2021-10-22
• Completion: 2021-11-21
• First posted: 2023-12-22
• Last updated: 2023-12-22

Locations

1 site across 1 country: United Kingdom

Regulatory

• FDA-regulated drug study